Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab vs Ustekinumab in Moderate to Severe Crohn's Disease
NCT04524611Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 31
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Sep 2020; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04524611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524611.